Mechanisms that determine nanocarrier targeting to healthy versus inflamed lung regions

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 13, Issue 4, 2017, Pages 1495-1506

  Brenner, Jacob S ^a,b   Bhamidipati, Kartik ^b   Glassman, Patrick M ^b   Ramakrishnan, N ^c   Jiang, Depeng ^d   Paris, Andrew J ^a   Myerson, Jacob W ^b   Pan, Daniel C ^b   Shuvaev, Vladimir V ^b   Villa, Carlos H ^b   Hood, Elizabeth D ^b   Kiseleva, Raisa ^b   Greineder, Colin F ^b   Radhakrishnan, Ravi ^c   Muzykantov, Vladimir R ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of Pennsylvania   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

ARDS; Inflammation; Nano bio interface; Nanocarriers; Nanoparticle biological interactions; Nanoparticles; Patchy; Spatial heterogeneity; Whole organ distribution

Indexed keywords

EPITOPES; NANOPARTICLES; PATHOLOGY; TISSUE;

ARDS; BIOINTERFACES; BIOLOGICAL INTERACTIONS; INFLAMMATION; NANO-CARRIERS; ORGAN DISTRIBUTION; PATCHY; SPATIAL HETEROGENEITY;

BIOLOGICAL ORGANS;

ANTIBODY; CD31 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LIPOSOME; MACROSALB TC 99M; NANOCARRIER; DRUG CARRIER; EPITOPE; NANOPARTICLE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AIR SAC; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; CAPILLARY LEAK SYNDROME; CONTROLLED STUDY; HYPOXIC LUNG VASOCONSTRICTION; LUNG BLOOD FLOW; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; PNEUMONIA; THIN LAYER CHROMATOGRAPHY; ANIMAL; C57BL MOUSE; CHEMISTRY; HYPOXIA; IMMUNOLOGY; INFLAMMATION; LUNG; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; VASOCONSTRICTION;

ANIMALS; ANTIBODIES; ANTIGENS, CD31; DRUG CARRIERS; EPITOPES; HYPOXIA; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; LUNG; MICE; MICE, INBRED C57BL; NANOPARTICLES; RESPIRATORY DISTRESS SYNDROME, ADULT; VASOCONSTRICTION;

EID: 85017241032     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.12.019     Document Type: Article

References (30)

1. 1 Uddin, M.J., Werfel, T.A., Crews, B.C., Gupta, M.K., Kavanaugh, T.E., Kingsley, P.J., et al. Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer. Biomaterials 92 (2016), 71–80.
2. 2 Zhou, H.-F., Yan, H., Hu, Y., Springer, L.E., Yang, X., Wickline, S.A., et al. Fumagillin prodrug nanotherapy suppresses macrophage inflammatory response via endothelial nitric oxide. ACS Nano 8 (2014), 7305–7317.
3. 3 Nguyen, M.M., Carlini, A.S., Chien, M.-P., Sonnenberg, S., Luo, C., Braden, R.L., et al. Enzyme-responsive nanoparticles for targeted accumulation and prolonged retention in heart tissue after myocardial infarction. Adv Mater 27 (2015), 5547–5552.
4. 4 Pan, D., Pham, C.T.N., Weilbaecher, K.N., Tomasson, M.H., Wickline, S.A., Lanza, G.M., Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 8 (2016), 85–106.
5. 5 Kowalski, P.S., Kuninty, P.R., Bijlsma, K.T., Stuart, M.C.A., Leus, N.G.J., Ruiters, M.H.J., et al. SAINT–liposome–polycation particles, a new carrier for improved delivery of siRNAs to inflamed endothelial cells. Eur J Pharm Biopharm 89 (2015), 40–47.
6. 6 Hiley, C.T., Swanton, C., Spatial and temporal cancer evolution: causes and consequences of tumour diversity. Clin Med 14:Suppl 6 (2014), s33–s37.
7. 7 Weidenbusch, M., Anders, H.-J., Tissue microenvironments define and get reinforced by macrophage phenotypes in homeostasis or during inflammation, repair and fibrosis. J Innate Immun 4 (2012), 463–477.
8. 8 Aird, W.C., Spatial and temporal dynamics of the endothelium. J Thromb Haemost 3 (2005), 1392–1406.
9. 9 González-García, I., Solé, R.V., Costa, J., Metapopulation dynamics and spatial heterogeneity in cancer. Proc Natl Acad Sci U S A 99 (2002), 13085–13089.
10. 10 Ju, J., Li, R., Gu, S., Leader, J.K., Wang, X., Chen, Y., et al. Impact of emphysema heterogeneity on pulmonary function. PLoS One, 9, 2014, e113320.
11. 11 Bellani, G., Laffey, J.G., Pham, T., Fan, E., Brochard, L., Esteban, A., et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315 (2016), 788–800.
12. 12 Matthay, M.A., Ware, L.B., Zimmerman, G.A., The acute respiratory distress syndrome. J Clin Invest 122 (2012), 2731–2740.
13. 13 Barth, P.J., Höltermann, W., Müller, B., The spatial distribution of pulmonary lesions in severe ARDS. An autopsy study of 35 cases. Pathol Res Pract 194 (1998), 465–471.
14. 14 Pesenti, A., Musch, G., Lichtenstein, D., Mojoli, F., Amato, M.B.P., Cinnella, G., et al. Imaging in acute respiratory distress syndrome. Intensive Care Med 42 (2016), 686–698.
15. 15 Wigenstam, E., Rocksén, D., Ekstrand-Hammarström, B., Bucht, A., Treatment with dexamethasone or liposome-encapsuled vitamin E provides beneficial effects after chemical-induced lung injury. Inhal Toxicol 21 (2009), 958–964.
16. 16 Herber-Jonat, S., Mittal, R., Gsinn, S., Bohnenkamp, H., Guenzi, E., Schulze, A., Comparison of lung accumulation of cationic liposomes in normal rats and LPS-treated rats. Inflamm Res 60 (2011), 245–253.
17. 17 Hegeman, M.A., Cobelens, P.M., Kamps, J., Hennus, M.P., Jansen, N.J.G., Schultz, M.J., et al. Liposome-encapsulated dexamethasone attenuates ventilator-induced lung inflammation. Br J Pharmacol 163 (2011), 1048–1058.
18. 18 Hood, E.D., Greineder, C.F., Dodia, C., Han, J., Mesaros, C., Shuvaev, V.V., et al. Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo. J Control Release 163 (2012), 161–169.
19. 19 Lin, X., Barravecchia, M., Kothari, P., Young, J.L., Dean, D.A., β1-Na(+),K(+)-ATPase gene therapy upregulates tight junctions to rescue lipopolysaccharide-induced acute lung injury. Gene Ther 23 (2016), 489–499.
20. 20 Brenner, J.S., Greineder, C., Shuvaev, V., Muzykantov, V., Endothelial nanomedicine for the treatment of pulmonary disease. Expert Opin Drug Deliv 12 (2015), 239–261.
21. 21 Preissler, G., Loehe, F., Huff, I.V., Ebersberger, U., Shuvaev, V.V., Bittmann, I., et al. Targeted endothelial delivery of nanosized catalase immunoconjugates protects lung grafts donated after cardiac death. Transplantation 92 (2011), 380–387.
22. 22 Fu, P., Birukova, A.A., Xing, J., Sammani, S., Murley, J.S., Garcia, J.G.N., et al. Amifostine reduces lung vascular permeability via suppression of inflammatory signalling. Eur Respir J 33 (2009), 612–624.
23. 23 Ferrer, M.C.C., Shuvaev, V.V., Zern, B.J., Composto, R.J., Muzykantov, V.R., Eckmann, D.M., Icam-1 targeted nanogels loaded with dexamethasone alleviate pulmonary inflammation. PLoS One, 9, 2014, e102329.
24. 24 Hellewell, P.G., Young, S.K., Henson, P.M., Worthen, G.S., Paradoxic effect of ibuprofen on neutrophil accumulation in pulmonary and cutaneous inflammation. Am J Respir Crit Care Med 151 (1995), 1218–1227.
25. 25 Hellewell, P.G., Henson, P.M., Downey, G.P., Worthen, G.S., Control of local blood flow in pulmonary inflammation: role for neutrophils, PAF, and thromboxane. J Appl Physiol 70 (1991), 1184–1193.
26. 26 Gattinoni, L., Caironi, P., Valenza, F., Carlesso, E., The role of CT-scan studies for the diagnosis and therapy of acute respiratory distress syndrome. Clin Chest Med 27 (2006), 559–570 [abstract vii].
27. 27 Cutaia, M., Rounds, S., Hypoxic pulmonary vasoconstriction. Physiologic significance, mechanism, and clinical relevance. Chest 97 (1990), 706–718.
28. 28 Sylvester, J.T., Shimoda, L.A., Aaronson, P.I., Ward, J.P.T., Hypoxic pulmonary vasoconstriction. Physiol Rev 92 (2012), 367–520.
29. 29 Hadad, N., Tuval, L., Elgazar-Carmom, V., Levy, R., Levy, R., Endothelial ICAM-1 protein induction is regulated by cytosolic phospholipase A2α via both NF-κB and CREB transcription factors. J Immunol 186 (2011), 1816–1827.
30. 30 Ellinghaus, P., Perzborn, E., Hauenschild, P., Gerdes, C., Heitmeier, S., Visser, M., et al. Expression of pro-inflammatory genes in human endothelial cells: comparison of rivaroxaban and dabigatran. Thromb Res 142 (2016), 44–51.